JCR Pharmaceuticals Co., Ltd. (4552.T)

813.00 -2.00 (-0.25%) At close: 03:15PM JST

JCR Pharmaceuticals Co., Ltd.

3-19 Kasuga-cho
Ashiya 659-0021
Japan
81 7 9732 8591
https://www.jcrpharm.co.jp

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 879

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Shin Ashida	Chairman, CEO & President	N/A	N/A	1943
Yoshihiro Ota	Director of Accounting Department & Corporate Strategy Department (Finance)	N/A	N/A	N/A
Yutaka Honda	Senior Corporate Officer, Executive Director of Administration Div. & Director of Human Resources	N/A	N/A	N/A
Hiroyuki Fukuya	Director of Legal Affairs Department - Administration Division	N/A	N/A	N/A
Toru Ashida	Senior VP of Sales & Administration, Executive Director of Sales Division and Director	N/A	N/A	1968
Ryutaro Makino	Director of Marketing Dept. & Group Manager of Product Planning - Marketing Dept. for Sales Div.	N/A	N/A	N/A
Katsuya Nishino	Executive Vice President	N/A	N/A	1956
Hiroshi Yoshimoto	Senior Advisor	N/A	N/A	1951
Takayo Egawa	Corporate Officer & Director of International Affairs Office	N/A	N/A	N/A
Mr. Hiroyuki Sonoda Ph.D.	VP of Research & Corporate Strategy, Executive Director of Research Division and Director	N/A	N/A	1978

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.

Description

JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

Corporate governance

JCR Pharmaceuticals Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.